STOCK TITAN

Processa (PCSA) CAO Wendy Guy adds 1,829 shares in open-market buy

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Processa Pharmaceuticals Chief Administrative Officer Wendy Guy reported an open-market purchase of 1,829 shares of Common Stock at $2.57 per share. After this trade, she directly owns 9,840 shares and is also shown with 333 shares held indirectly through CorLyst, LLC.

Positive

  • None.

Negative

  • None.
Insider Guy Wendy
Role Chief Administrative Officer
Bought 1,829 shs ($5K)
Type Security Shares Price Value
Purchase Common Stock 1,829 $2.57 $5K
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 9,840 shares (Direct, null); Common Stock — 333 shares (Indirect, By CorLyst, LLC)
Footnotes (1)
Shares purchased 1,829 shares Open-market purchase of Common Stock
Purchase price $2.57 per share Cost per share for the 1,829-share buy
Direct holdings after transaction 9,840 shares Common Stock directly owned following the purchase
Indirect holdings 333 shares Common Stock held indirectly through CorLyst, LLC
open-market purchase financial
"transaction_action: open-market purchase"
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
indirect ownership financial
"ownership_type: indirect, nature_of_ownership: By CorLyst, LLC"
Common Stock financial
"security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
Form 4 regulatory
"INSIDER FILING DATA (Form 4)"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Guy Wendy

(Last)(First)(Middle)
C/O PROCESSA PHARMACEUTICALS, INC.
601 21ST STREET SUITE 300

(Street)
VERO BEACH FLORIDA 32960

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Processa Pharmaceuticals, Inc. [ PCSA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Administrative Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/29/2026P1,829A$2.579,840D
Common Stock333IBy CorLyst, LLC
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
/s/ Wendy Guy by John J. Wolfel, as Attorney-in-Fact06/01/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did PCSA executive Wendy Guy report?

Wendy Guy reported buying 1,829 shares of Processa Pharmaceuticals Common Stock in an open-market transaction. The shares were purchased at $2.57 per share, indicating a direct increase in her equity stake in the company.

At what price did Wendy Guy buy Processa Pharmaceuticals (PCSA) shares?

She bought Processa Pharmaceuticals Common Stock at $2.57 per share. This price reflects the cost of the 1,829 shares acquired in the reported open-market purchase on the transaction date disclosed in the Form 4.

How many Processa Pharmaceuticals shares does Wendy Guy hold after this Form 4?

Following the reported transaction, Wendy Guy directly holds 9,840 shares of Processa Pharmaceuticals Common Stock. The filing also lists 333 additional shares as being held indirectly through CorLyst, LLC associated with her.

Is the PCSA insider transaction by Wendy Guy a buy or sell?

The Form 4 shows a buy transaction. Wendy Guy completed an open-market purchase of 1,829 shares of Processa Pharmaceuticals Common Stock, increasing her direct holdings rather than disposing of existing shares.

Does Wendy Guy have indirect ownership of PCSA shares?

Yes. In addition to her direct holdings, the Form 4 lists 333 shares of Processa Pharmaceuticals Common Stock as indirectly owned by Wendy Guy through CorLyst, LLC, indicating a separate indirect ownership position.